BioCentury
ARTICLE | Tools & Techniques

Mammoth eyes CRISPR-based therapeutics with new funding

CRISPR company Mammoth looks beyond diagnostics with Decheng Capital-led $45M series B

January 30, 2020 5:02 PM UTC
Updated on Jan 31, 2020 at 6:47 AM UTC

With a $45 million series B round led by Decheng Capital, Mammoth Biosciences is capitalizing on its IP position around an alternative CRISPR enzyme and expanding its gene editing capabilities beyond diagnostics into a range of therapeutic applications.

Mayfield, NFX, Verily and Brook Byers also participated in the round, which brings the company’s total funding to over $70 million to date. ...

BCIQ Company Profiles

Mammoth Biosciences Inc.